PT - JOURNAL ARTICLE AU - KREJCI, DANIEL AU - OPALKA, PETR AU - KREJCI, JANA AU - ZEMANOVA, MILADA AU - ZEMANOVA, PETRA AU - KULTAN, JURAJ AU - FISCHER, ONDREJ AU - SKRICKOVA, JANA AU - BRATOVA, MONIKA AU - CERNOVSKA, MARKETA AU - HRNCIARIK, MICHAL AU - COUPKOVA, HELENA AU - HURDALKOVA, KAROLINA AU - BARINOVA, MAGDA AU - KOUBKOVA, LEONA AU - DOLEZAL, DANIEL AU - SAFANDA, MARTIN AU - PESEK, MILOS AU - SVATON, MARTIN TI - Comparison of Chemotherapeutic Regimens Frequently Used in Metastatic Non-squamous NSCLC Treatment AID - 10.21873/anticanres.15039 DP - 2021 May 01 TA - Anticancer Research PG - 2597--2603 VI - 41 IP - 5 4099 - http://ar.iiarjournals.org/content/41/5/2597.short 4100 - http://ar.iiarjournals.org/content/41/5/2597.full SO - Anticancer Res2021 May 01; 41 AB - Background/Aim: Platinum-based chemotherapy with pemetrexed or paclitaxel/bevacizumab are regimens used in combination with checkpoint inhibitors in non-squamous non-small cell lung cancer (NSCLC) treatment. We conducted a real-world study to compare the outcomes of these chemotherapeutic regimens. Patients and Methods: We investigated 1,534 patients with advanced non-squamous NSCLC treated with platin/pemetrexed (n=1212) or platin/paclitaxel/bevacizumab (n=322) in 9 cancer centres in the Czech Republic. Results: The regimen containing platin/paclitaxel/bevacizumab showed significantly better overall response rate (ORR) compared to the platin/pemetrexed [40.8% vs. 32.7% (p=0.008)] in the overall population and [55.0% vs. 38.8% (p=0.002)] in the Eastern Cooperative Oncology Group performance status 0 group. There was no significant improvement in progression-free survival (PFS) and overall survival (OS) in either of these two groups of patients. Conclusion: In our real-world data analysis, patients treated with platin/paclitaxel/bevacizumab had better overall response rate (ORR), but not PFS or OS. Thus, both treatment regimens are similarly effective. Their selection should therefore be based on the potential side effects.